Alpha-9 Oncology is a clinical-stage biopharmaceutical company founded in 2019 by renowned scientists based at BC Cancer and the University of British Columbia.

The Company is using its world-class know-how in molecular design and targeting of radiotherapeutics to advance a portfolio of breakthrough technologies focused on the precision targeting of metastatic cancer. These technologies promise to potentially revolutionize the way in which metastatic cancer is both diagnosed and treated.